If the industry intends to resist a new statutory pricing framework, which would be fair enough, it must honestly consider what that would look like in practice. Is it prepared to manage the short-term consequences? Is it able to withstand political pressure, public scrutiny, and the effects on its day-to-day dealings with the Government?
The industry is probably right to resist, it just needs to prepare for the response
December 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News

